Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE Healthcare Commits To China’s Basic Health Care

This article was originally published in PharmAsia News

Executive Summary

GE Healthcare announced that it will further strengthen support for basic health care in China's rural areas, promising to launch five new products by 2010 to meet requirements of the market. The firm has given R&D priority to develop high-tech but low-price products since 2006. Items suitable for rural areas such as ultrasonic diagnosis devices, patient monitor systems, EKG and anesthesia facilities have contributed to GE Healthcare's 30 percent marketshare in China and the figure is rising. To align with the health care reform, GE Healthcare has specially mapped out a tier-two market strategy that supplies basic health care products with high performance-price ratios to rural hospitals, making early diagnosis accessible to the rural community. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel